Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PANITUMUMAB Cause Malignant neoplasm progression? 162 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 162 reports of Malignant neoplasm progression have been filed in association with PANITUMUMAB (Vectibix). This represents 1.5% of all adverse event reports for PANITUMUMAB.

162
Reports of Malignant neoplasm progression with PANITUMUMAB
1.5%
of all PANITUMUMAB reports
58
Deaths
19
Hospitalizations

How Dangerous Is Malignant neoplasm progression From PANITUMUMAB?

Of the 162 reports, 58 (35.8%) resulted in death, 19 (11.7%) required hospitalization, and 3 (1.9%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PANITUMUMAB. However, 162 reports have been filed with the FAERS database.

What Other Side Effects Does PANITUMUMAB Cause?

Rash (1,392) Diarrhoea (1,123) Death (767) Dermatitis acneiform (758) Neutropenia (757) Skin toxicity (728) Neuropathy peripheral (613) Hypomagnesaemia (611) Nausea (608) Disease progression (600)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which PANITUMUMAB Alternatives Have Lower Malignant neoplasm progression Risk?

PANITUMUMAB vs PANOBINOSTAT PANITUMUMAB vs PANTOPRAZOLE PANITUMUMAB vs PANTOPRAZOLE ANHYDROUS PANITUMUMAB vs PANTOTHENIC ACID PANITUMUMAB vs PAPAVERINE

Related Pages

PANITUMUMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression PANITUMUMAB Demographics